Ivermectin helped people RECOVER FASTER from COVID-19 infections, study finds
By Ava Grace // Mar 14, 2024

A study has once again attested to the ability of anti-parasitic drug ivermectin against the Wuhan coronavirus (COVID-19), with the said paper finding that it helped people recover faster from infection.

The study published Feb. 29 in the Journal of Infection (JoI) involved 8,811 participants who tested positive for COVID-19 in the so-called PRINCIPLE Trial. Of this number, 2,157 were given ivermectin as treatment. The other 3,398 participants received other treatments, while the remaining 3,256 received the usual standard of care for COVID-19 infection.

The study was conducted from June 23, 2021 to July 1, 2022. It ultimately found that the ivermectin recipients had a shorter recovery period – a median of two days – compared to the other two groups. Those who received ivermectin were also less likely to be hospitalized or die, with 1.6 percent of participants in this group suffering from these outcomes. In contrast, four percent of the usual care group died of COVID-19, if not hospitalized.

Moreover, ivermectin recipients also enjoyed a reduction of severe symptoms and sustained recovery. Despite this promising discovery, the study authors absurdly discouraged the use of ivermectin to treat COVID-19. (Related: Ivermectin is trending again… New scientific paper released exposing "miracle drug.")

"Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement for recovery, hospital admissions or longer-term outcomes. Further trials of ivermectin for SARS-CoV-2 infection in vaccinated community populations appear unwarranted," they wrote in the study's interpretation section.

Human knowledge is under attack! Governments and powerful corporations are using censorship to wipe out humanity's knowledge base about nutrition, herbs, self-reliance, natural immunity, food production, preparedness and much more. We are preserving human knowledge using AI technology while building the infrastructure of human freedom. Speak freely without censorship at the new decentralized, blockchain-power Brighteon.io. Explore our free, downloadable generative AI tools at Brighteon.AI. Support our efforts to build the infrastructure of human freedom by shopping at HealthRangerStore.com, featuring lab-tested, certified organic, non-GMO foods and nutritional solutions.

They ultimately concluded: "The results from our trial … support the position that ivermectin should not be used to treat SARS-CoV-2 infection in the community in high-income countries with a largely vaccinated population. We consider that additional studies of ivermectin in this population should not be a priority for research."

According to the Epoch Times, the study authors involved in the PRINCIPLE Trial divulged conflicts of interest in their paper. One co-author received grants from pharmaceutical companies including AstraZeneca, while other disclosed receiving grants from the University of Oxford. Incidentally, the university was instrumental in developing AstraZeneca's COVID-19 vaccine that uses an adenovirus vector.

Study wrongly downplayed how ivermectin improved recovery from COVID-19

Dr. Christopher Butler, the study's corresponding author, said: "Ivermectin is readily available globally [and] has been in wide use for many other infectious conditions. It's a well-known medicine with a good safety profile and because of the early promising results in some studies, it is already being widely used to treat COVID-19 in several countries.

However, the decision of Butler and his co-authors to smear ivermectin in their study despite acknowledging its effects against SARS-CoV-2 has left many scratching their heads. This led to American physician Dr. Pierre Kory to accuse the authors of "setting a new record for ivermectin research fraud." According to him, Butler and his colleagues wrongly downplayed how ivermectin improved recovery from COVID-19.

"PRINCIPLE was a profoundly positive study that was instead analyzed and written up as a negative one," Kory wrote in a March 5 piece on his Substack. The co-founder and president of the Front Line COVID-19 Critical Care Alliance (FLCCC) has long promoted ivermectin as a COVID-19 treatment over the deadly COVID-19 injections.

"The millions of patients and doctors around the world who know how effective and safe of an antiviral [ivermectin] is will continue to use it for COVID-19, flu, Disease X and beyond."

Watch Dr. Pierre Kory testify to the effectiveness of ivermectin against COVID-19, citing a study that involved more than 500,000 participants to back up his testimony.

This video is from the GalacticStorm channel on Brighteon.com.

More related stories:

Ivermectin available over the counter in Tennessee.

Ivermectin works, even if the establishment falsely claims otherwise.

Ivermectin smuggled in chocolate bar saves British Covid patient’s life.

Family of woman who DIED after being refused IVERMECTIN speaks out.

FDA now admits doctors can prescribe IVERMECTIN to treat COVID-19

Sources include:

TheEpochTimes.com

JournalOfInfection.com

PierreKoryMedicalMusings.com

Brighteon.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.